Project Grant R21AI202488
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $273K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $152,600 on October 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the neural basis of spatial repellency in the malaria mosquito Anopheles gambiae. The research identifies active ingredients in lemongrass oil species (Cymbopogon citratus, Cymbopogon flexuosus, and Cymbopogon pendulus) that drive spatial repellency and determines the underlying...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, San Diego $480,000 on September 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the molecular basis for arboviral fitness in vector and reservoir hosts. The research examines how arboviruses replicate across evolutionarily distant hosts—insects and vertebrates—despite showing high specificity in their transmission cycles. Using alphaviruses as a...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Dakota $207,810 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish the duration of mosquitocidal efficacy for two isoxazoline drugs, fluralaner and lotilaner, when ingested by relevant vertebrate species involved in the transmission of West Nile virus and malaria. The project focuses on determining how long a single dose of isoxazoline drug can continue...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $788,379 on June 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into the adaptive response of Plasmodium falciparum parasites to sickle-trait erythrocytes. The project, titled PARSEC (Plasmodium falciparum Adaptive Response to Sickle Trait Erythrocytes), investigates mechanisms by which sickle-trait hemoglobin confers protection against severe malaria in African...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $148,614 on March 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support interdisciplinary training and research experience in vector-borne disease epidemiology, migration, and environmental health. The award funds a fellowship supporting mentored training in the assessment of malaria transmission dynamics near migrant communities in Panama's Darien and Guna Yala regions....
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Greensboro $1,446,657 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 10, 2025, for research on the behavioral, microbial, and chemical ecology of sand fly oviposition site selection. The research investigates oviposition behavior and host-seeking mechanisms in Phlebotomus papatasi, the principal vector of Leishmania major in arid Old World regions. The...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $2.178 million on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate chemosensory mechanisms by which the African malaria mosquito Anopheles gambiae detects and responds to human body odor to facilitate malaria transmission. The research identifies volatile organic compounds in human scent signatures correlated with mosquito attraction and...
- The National Institute of Allergy and Infectious Diseases awarded Kansas State University $738,183 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the immunoregulatory protease network that controls melanization in Anopheles gambiae, the African malaria mosquito vector. The research identifies molecular interactions that regulate phenoloxidase activation and melanization cascade proteases, with the objective of understanding how protease...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $198,728 on February 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate visual-olfactory learning and integration in the yellow fever mosquito, Aedes aegypti. The research addresses how mosquitoes combine visual and olfactory sensory cues to locate and feed on hosts. Specific Aim 1 examines multimodal learning and memory of visual and olfactory stimuli...
- The National Institute of Allergy and Infectious Diseases awarded $765,496 to the University of California, Davis on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop recombinant enhanced antiviral restrictors (REAVRs) that broadly inhibit known and emerging viruses to control or prevent vector-borne and zoonotic viral diseases. The project will generate and optimize REAVR proteins by combining virus-sensing domains with effector domains from...